{"id":"ex-vivo-expanded-effector-cells","_chembl":{"chemblId":"CHEMBL5315099","moleculeType":"Unknown"},"modality":"Biologic","_dailymed":null,"mechanism":{"explanation":"The therapy involves harvesting immune effector cells from a patient, culturing them ex-vivo to dramatically increase their population, and then reinfusing the expanded cells back into the patient. This approach aims to boost the patient's immune system by providing a larger army of functional immune cells.","oneSentence":"Immune effector cells are collected from patients, expanded in laboratory culture to increase their numbers, then reinfused to enhance immune response."},"_scrapedAt":"2026-03-28T01:52:37.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123520,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"tisagenlecleucel","brand":"Kymriah","company":"Novartis","rationale":"CAR-T cell therapy involving ex-vivo manipulation of immune cells"},{"name":"axicabtagene ciloleucel","brand":"Yescarta","company":"Gilead/Kite","rationale":"CAR-T cell therapy with ex-vivo cell expansion approach"}],"description":"Ex-vivo expanded effector cells are immune cells grown outside the body in laboratory conditions to increase their numbers before being returned to the patient. This cell therapy approach is being investigated by Dartmouth-Hitchcock Medical Center in Phase 2 clinical trials for potential therapeutic applications.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT00439465","phase":"PHASE2","title":"Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2007-01","conditions":"Myeloma, Transplant-eligible Patients","enrollment":23},{"nctId":"NCT01329354","phase":"PHASE2","title":"Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2011-03","conditions":"Follicular Lymphoma, Follicular Non-Hodgkin´s Lymphoma, Autologous Effector Lymphocytes","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Ex-vivo expanded effector cells","genericName":"Ex-vivo expanded effector cells","companyName":"Dartmouth-Hitchcock Medical Center","companyId":"dartmouth-hitchcock-medical-center","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}